Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
As of March 2025 Novo Nordisk has a market cap of โฌ305.23 Billion. This makes Novo Nordisk the world's 27th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Marketcap | Change |
---|---|---|
2025 | โฌ305.23 B | -17.29% |
2024 | โฌ369.06 B | -11.54% |
2023 | โฌ417.21 B | 46.97% |
2022 | โฌ283.87 B | 26.04% |
2021 | โฌ225.22 B | 69.88% |
2020 | โฌ132.58 B | 6.76% |
2019 | โฌ124.19 B | 27.07% |
2018 | โฌ97.73 B | -10.57% |
2017 | โฌ109.28 B | 22.07% |
2016 | โฌ89.53 B | -35.72% |
2015 | โฌ139.29 B | 50.42% |
2014 | โฌ92.60 B | 26.38% |
2013 | โฌ73.27 B | 6.55% |
2012 | โฌ68.76 B | 33.88% |
2011 | โฌ51.36 B | 1.16% |
2010 | โฌ50.77 B | 79.72% |
2009 | โฌ28.25 B | 21.24% |
2008 | โฌ23.30 B | -18.91% |
2007 | โฌ28.74 B | 42.94% |
2006 | โฌ20.10 B | 30.74% |
2005 | โฌ15.37 B | 15.77% |
2004 | โฌ13.28 B | 18.25% |
2003 | โฌ11.23 B | 16.71% |
2002 | โฌ9.62 B | -38.85% |
2001 | โฌ15.74 B | 19.96% |
2000 | โฌ13.12 B | 44.04% |
1999 | โฌ9.10 B | 12.13% |
1998 | โฌ8.12 B | -10.92% |
1997 | โฌ9.12 B | 54.34% |
1996 | โฌ5.90 B |
On Mar 25th, 2025 the market cap of Novo Nordisk was reported to be: